Stay up-to-date
Follow us on social media
Grifols concludes balance sheet improvement process with private placement of Senior Secured Notes and Revolving Credit Facility extension
Grifols’ Board of Directors Announces Termination of Acquisition Discussions with Brookfield
GigaGen Doses First Patient in Phase 1 Trial of Recombinant Polyclonal Drug Candidate, GIGA-2339, for Hepatitis B Virus
Follow us on social media
Our media relations team can be reached at:
(+34) 93 571 00 02
media@grifols.com.
Restricted to media inquiries only.
For general questions and requests, please contact corporatecomms@grifols.com.
Press Releases
Stay up-to-date on corporate developments as well as innovations in our plasma-derived medicines and other products and solutions.
Company Statements
Our official position on important matters.